- MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma2018 | First Faculty of Medicine
- Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy2024 | Publication without faculty affiliation
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial2018 | Publication without faculty affiliation
- Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis2014 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine
- Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib2017 | Publication without faculty affiliation
- New possibilities of targeted therapy of thyroid cancer2017 | Publication without faculty affiliation
- Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study2020 | Faculty of Medicine in Hradec Králové
- Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion2019 | Faculty of Medicine in Hradec Králové
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study2018 | Second Faculty of Medicine